Purple Biotech Ltd. - Report Publication Announcement 2021

6K:Purple Biotech Expands ResearchCollaboration in Immuno-Oncology in Combination with NT219 false


	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	26/10/2021
	www.isa.gov.il			www.tase.co.il				Reference:	2021-02-159954	Time of broadcast: 15:30 15:30

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on6K:Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

ea149334-6k_purplebioEDGAR2_bannerless_isa.pdf


6K- �� -�� NT219
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 19/10/2021
Address: Oppenheimer, Science Park 4 , Rehovot 7670104 , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: [email protected] Company site: www.kitovpharma.com

Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,

Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: [email protected] 1
Israel

AI assistant